


World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2011 March 27; 3(3): 31-42





Editorial Board

2009-2013

The *World Journal of Gastrointestinal Surgery* Editorial Board consists of 336 members, representing a team of worldwide experts in gastrointestinal surgery research. They are from 35 countries, including Australia (6), Austria (2), Belgium (6), Brazil (9), Bulgaria (2), Canada (8), China (30), Denmark (1), Finland (1), France (10), Germany (22), Greece (6), India (10), Ireland (3), Israel (3), Italy (48), Jamaica (1), Japan (47), Malaysia (1), Netherlands (9), Pakistan (1), Poland (1), Portugal (1), Russia (1), Singapore (6), Serbia (1), South Korea (9), Spain (5), Sweden (2), Switzerland (4), Thailand (2), Tunisia (1), Turkey (8), United Kingdom (7), and United State (62).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Elijah Dixon, *Calgary*
Antonello Forgione, *Milan*
Tobias Keck, *Freiburg*
Tsuyoshi Konishi, *Tokyo*
Natale Di Martino, *Naples*

GUEST EDITORIAL BOARD MEMBERS

Chao-Long Chen, *Kaohsiung*
Chien-Hung Chen, *Taipei*
Jong-Shiaw Jin, *Taipei*
Chen-Guo Ker, *Kaohsiung*
King-Teh Lee, *Kaohsiung*
Wei-Jei Lee, *Taoyuan*
Shiu-Ru Lin, *Kaohsiung*
Wan-Yu Lin, *Taichung*
Yan-Shen Shan, *Tainan*
Jaw-Yuan Wang, *Kaohsiung*
Li-Wha Wu, *Tainan*
Fang Hsin-Yuan, *Taichung*

MEMBERS OF THE EDITORIAL BOARD



Australia

Ned Abraham, *Coffs Harbour*
Christopher Christophi, *Melbourne*
M Michael, *Victoria*
David Lawson Morris, *Kogarah*
Jas Singh Samra, *St Leonards*
Matthias W Wichmann, *Millicent*



Austria

Harald R Rosen, *Vienna*
Franz Sellner, *Vienna*



Belgium

Giovanni Dapri, *Brussels*
Jean-François Gigot, *Brussels*
Lerut Jan Paul Marthe, *Brussels*
Gregory Peter Sergeant, *Leuven*
Hans Van Vlierberghe, *Gent*
Jean-Louis Vincent, *Brussels*



Brazil

Jose E Aguilar-Nascimento, *Cuiaba*
MR Álvares-da-Silva, *Porto Alegre*
Fernando M Biscione, *Minas Gerais*
Julio Coelho, *Curitiba*
Marcel A Machado, *São Paulo*
MAF Ribeiro Jr, *Santana de Parnaíba*
José Sebastião dos Santos, *São Paulo*
Marcus VM Valadão, *Rio de Janeiro*
Ricardo Zorron, *Rio de Janeiro*



Bulgaria

Krassimir D Ivanov, *Varna*
Belev Nikolai, *Plovdiv*



Canada

Runjan Chetty, *Toronto*

Laura A Dawson, *Toronto*
Mahmoud A Khalifa, *Toronto*
Peter Kim, *Toronto*
Peter Metrakos, *Quebec*
Reda S Saad, *Toronto*
Manuela Santos, *Montreal*



China

Yue-Zu Fan, *Shanghai*
Wen-Tao Fang, *Shanghai*
Yong-Song Guan, *Chengdu*
Shao-Liang Han, *Wenzhou*
Michael G Irwin, *Hong Kong*
Long Jiang, *Shanghai*
Wai Lun Law, *Hong Kong*
Ting-Bo Liang, *Hangzhou*
Quan-Da Liu, *Beijing*
Yu-Bin Liu, *Guangdong*
Ding Ma, *Wuhan*
Jian-Yang Ma, *Chengdu*
Kwan Man, *Hong Kong*
Tang Chung Ngai, *Hong Kong*
Yan-Ning Qian, *Nanjing*
Ai-Wen Wu, *Beijing*
Yin-Mo Yang, *Beijing*
Yun-Fei Yuan, *Guangzhou*



Denmark

Thue Bisgaard, *Lykkebæk*



Finland

Helena M Isoniemi, *Helsinki*



France

Chapel Alain, *Far*
 Mustapha Adham, *Lyon*
 Brice Gayet, *Paris*
 Jean-François Gillion, *Antony*
 D Heresbach, *Rennes Cedex*
 Romaric Loffroy, *Dijon Cedex*
 Jacques Marescaux, *Strasbourg Cedex*
 Yves Panis, *Clichy*
 Aurélie Plessier, *Clichy*
 Eric Savier, *Paris*



Germany

Vollmar Brigitte, *Rostock*
 Dieter C Broering, *Kiel*
 Hans G Beger, *Ulm*
 Ansgar M Chromik, *Bochum*
 Marc-H Dahlke, *Regensburg*
 Irene Esposito, *Neuherberg*
 Stefan Fichtner-Feigl, *Regensburg*
 Benedikt Josef Folz, *Bad Lippspringe*
 Helmut Friess, *München*
 Reinhart T Grundmann, *Burghausen*
 Bertram Illert, *Würzburg*
 Jakob R Izbicki, *Hamburg*
 Haier Jörg, *Münster*
 Jörg H Kleeff, *Munich*
 Axel Kleespies, *Munich*
 Uwe Klinge, *Aachen*
 Martin G Mack, *Frankfurt*
 Klaus Erik Mönkemüller, *Bottrop*
 Matthias Peiper, *Dusseldorf*
 Hubert Scheidbach, *Magdeburg*
 Joerg Theisen, *Munich*



Greece

Elco de Bree, *Herakleion*
 Stavros J Gourgiotis, *Athens*
 Andreas Manouras, *Athens*
 Theodoros E Pavlidis, *Thessaloniki*
 George H Sakorafas, *Athens*
 Vassilios E Smyrniotis, *Athens*



India

Anil K Agarwal, *New Delhi*
 Shams-ul-Bari, *Kashmir*
 Somprakas Basu, *Varanasi*
 Pravin J Gupta, *Nagpur*
 Vinay Kumar Kapoor, *Lucknow*
 Chandra Kant Pandey, *Lucknow*
 Shailesh V Shrikhande, *Mumbai*
 Sadiq S Sikora, *Bangalore*
 Prod Rakesh K Tandon, *New Delhi*
 Imtiaz Ahmed Wani, *Srinagar*



Ireland

Kevin C P Conlon, *Dublin*

Prem Puri, *Dublin*
 Eamonn M Quigley, *Cork*



Israel

Tulchinsky Hagit, *Tel Aviv*
 Ariel Halevy, *Zerifin*
 Jesse Lachter, *Haifa*



Italy

Angelo Andriulli, *San Giovanni Rotondo*
 Giuseppe Aprile, *Udine*
 Gianni Biancofiore, *Pisa*
 Stefania Boccia, *Rome*
 Luigi Bonavina, *San Donato*
 Pier Andrea Borea, *Ferrara*
 Giovanni Cesana, *Milan*
 Stefano Crippa, *Verona*
 Giovanni D De Palma, *Napoli*
 Giovanni De Simone, *Napoli*
 Giuseppe Malleo, *Verona*
 Giorgio Ercolani, *Bologna*
 Carlo Feo, *Ferrara*
 Simone Ferrero, *Genova*
 Valenza Franco, *Milano*
 Leandro Gennari, *Rozzano*
 Felice Giuliant, *Roma*
 Salvatore Gruttadauria, *Palermo*
 Calogero Iacono, *Verona*
 Riccardo Lencioni, *Pisa*
 Dottor Fabrizio Luca, *Milan*
 Paolo Massucco, *Candiolo*
 Giorgio Di Matteo, *Roma*
 Giulio Melloni, *Milan*
 Manuela Merli, *Roma*
 Paolo Morgagni, *Forlì*
 Chiara Mussi, *Rozzano*
 Gabriella Nesi, *Florence*
 Angelo Nespoli, *Monza*
 Fabio Pacelli, *Rome*
 Corrado Pedrazzani, *Siena*
 Roberto Persiani, *Rome*
 Piero Portincasa, *Bari*
 Pasquale Petronella, *Napoli*
 Stefano Rauseri, *Varese*
 Carla Ida Ripamonti, *Milan*
 Antonio Russo, *Palermo*
 Giulio A Santoro, *Treviso*
 Stefano Scabini, *Genoa*
 Gianfranco Silecchia, *Roma*
 Guido AM Tiberio, *Brescia*
 Umberto Veronesi, *Milano*
 Bruno Vincenzi, *Rome*
 Marco Vivarelli, *Bologna*
 Alberto Zaniboni, *Brescia*
 Alessandro Zerbi, *Milan*



Jamaica

Joseph M Plummer, *Kingston*



Japan

Yasunori Akutsu, *Chiba*

Ryuichiro Doi, *Kyoto*
 Yosuke Fukunaga, *Sakai*
 Akira Furukawa, *Shiga*
 Shigeru Goto, *Oita*
 Kazuhiko Hayashi, *Tokyo*
 Naoki Hiki, *Tokyo*
 Takeyama Hiromitsu, *Nagoya*
 Tsujimoto Hironori, *Tokorozaawa*
 Tsukasa Hotta, *Wakayama*
 Yutaka Iida, *Gifu*
 Kazuaki Inoue, *Yokohama*
 Masashi Ishikawa, *Tokushima*
 Tatsuo Kanda, *Niigata*
 Tatsuyuki Kawano, *Tokyo*
 Keiji Koda, *Chiba*
 Hajime Kubo, *Kyoto*
 Iruru Maetani, *Tokyo*
 Yoshimasa Maniwa, *Kobe*
 Toru Mizuguchi, *Hokkaido*
 Zenichi Morise, *Toyoake*
 Yoshihiro Moriwaki, *Yokohama*
 Yoshihiro Moriya, *Tokyo*
 Satoru Motoyama, *Akita*
 Hiroaki Nagano, *Osaka*
 Masato Nagino, *Nagoya*
 Toshio Nakagohri, *Kashiwa*
 Kazuyuki Nakamura, *Yamaguchi*
 Shingo Noura, *Osaka*
 Kazuo Ohashi, *Tokyo*
 Yoichi Sakurai, *Toyoake*
 Hirozumi Sawai, *Nagoya*
 Masayuki Sho, *Nara*
 Yasuhiko Sugawara, *Tokyo*
 Hiroshi Takamori, *Kumamoto*
 Sonshin Takao, *Kagoshima*
 Kuniya Tanaka, *Yokohama*
 Masanori Tokunaga, *Shizuoka*
 Yasunobu Tsujinaka, *Kashiwa*
 Akira Tsunoda, *Kamogawa*
 Toshifumi Wakai, *Niigata*
 Jiro Watari, *Nishinomiya*
 Shinichi Yachida, *Kagawa*
 Yasushi Yamauchi, *Fukuoka*
 Hiroki Yamaue, *Wakayama*
 Yutaka Yonemura, *Osaka*



Malaysia

Way Seah Lee, *Kuala Lumpur*



Netherlands

Lee H Bouwman, *Hague*
 Wim A Buuman, *Maastricht*
 Robert Chamuleau, *Amsterdam*
 Miguel A Cuesta, *Amsterdam*
 Jeroen Heemskerk, *Roermond*
 Buis Carlijn Ineke, *Deventer*
 Wjhj Meijerink, *Amsterdam*
 Chj van Eijck, *Rotterdam*
 Alexander L Vahrmeijer, *Leiden*



Pakistan

Kamran Khalid, *Lahore*

**Poland**

Bogusław Machaliński, *Szczecin*

**Portugal**

Jorge Correia-Pinto, *Braga*

**Russia**

Grigory G Karmazanovsky, *Moscow*

**Singapore**

Brian KP Goh, *Singapore*
Salleh bin Ibrahim, *Singapore*
John M Luk, *Singapore*
Francis Seow-Choen, *Singapore*
Vishalkumar G Shelat, *Singapore*
Melissa Teo, *Singapore*

**Serbia**

Ivan Jovanovic, *Belgrade*

**South Korea**

Joon Koo Han, *Seoul*
Hyung-Ho Kim, *Seongnam*
Woo Ho Kim, *Seoul*
Sang Y Lee, *Gyeongangnam-do*
Woo Yong Lee, *Seoul*
Hyo K Lim, *Seoul*
Jae-Hyung Noh, *Seoul*
Sung Hoon Noh, *Seoul*
Hee Jung Wang, *Suwon*

**Spain**

Antonio M Lacy Fortuny, *Barcelona*
Laura L Garriga, *Barcelona*
Francisco José Vizoso, *Gijón*
David Parés, *Sant Boi de Llobregat*
Prieto Jesus, *Pamplona*

**Sweden**

Helgi Birgisson, *Uppsala*
Jörgen Rutegård, *Umeå*

**Switzerland**

Andrea Frilling, *Zürich*
Pascal Gervaz, *Genève*
Bucher Pascal, *Geneva*
Marc Pusztaszeri, *Carouge*

**Thailand**

Varut Lohsiriwat, *Bangkok*
Rungsun Rerknimitr, *Bangkok*

**Tunisia**

Nafaa Arfa, *Tunis*

**Turkey**

Ziya Anadol, *Ankara*
Unal Aydin, *Gaziantep*
Mehmet Fatih Can, *Ankara*
Gözde Kir, *Istanbul*
Adnan Narci, *Afyonkarahisar*
Ilgin Ozden, *Istanbul*
Mesut Abdulkirim Ünsal, *Trabzon*
Omer Yoldas, *Ordu*

**United Kingdom**

Graeme Alexander, *Cambridge*
Simon R Bramhall, *Birmingham*
Giuseppe Fusai, *London*
Najib Haboubi, *Manchester*
Gianpiero Gravante, *Leicester*
Aftab Alam Khan, *Kent*
Caroline S Verbeke, *Leeds*

**United States**

Eddie K Abdalla, *Houston*

Forse Robert Armour, *Omaha*
Samik K Bandyopadhyay, *Kolkata*
Marc D Basson, *Lansing*
James M Becker, *Boston*
Thomas D Boyer, *Tucson*
Michael E de Vera, *Pittsburgh*
Andrew J Duffy, *New Haven*
Kelli Bullard Dunn, *Buffalo*
Thomas Fabian, *New Haven*
P Marco Fisichella, *Maywood*
Raja M Flores, *New York*
Markus Frank, *Boston*
Niraj J Gusani, *Hershey*
Douglas W Hanto, *Boston*
John P Hoffman, *Philadelphia*
Scott A Hundahl, *California*
Michel Kahaleh, *Charlottesville*
David S Kauvar, *Maryland*
Mary M Kemeny, *New York*
Nancy E Kemeny, *New York*
Vijay P Khatri, *Sacramento*
Joseph Kim, *Duarte*
Andrew Klein, *Los Angeles*
Richard A Kozarek, *Seattle*
Robert A Kozol, *Farmington*
Sunil Krishnan, *Houston*
Atul Kumar, *New York*
Wei Li, *Seattle*
Keith D Lillemoe, *Indianapolis*
Henry T Lynch, *Omaha*
Paul Ellis Marik, *Philadelphia*
Robert C Miller, *Rochester*
Thomas J Miner, *Providence*
Ravi Murthy, *Houston*
Atsunori Nakao, *Pittsburgh*
Hirofumi Noguchi, *Dallas*
Jeffrey A Norton, *Stanford*
Timothy M Pawlik, *Baltimore*
Nicholas J Petrelli, *Newark*
Alessio Pigazzi, *Duarte*
James John Pomposelli, *Carlisle*
Mitchell C Posner, *Chicago*
Alexander S Rosemurgy, *Florida*
Ng Chaaan S, *Houston*
Sukamal Saha, *Flint*
Reza F Saidi, *Boston*
Aaron R Sasson, *Omaha*
Christian M Schmidt, *Indianapolis*
Perry Shen, *Winston-Salem*
Ali A Siddiqui, *Dallas*
Frank A Sinicrope, *Rochester*
Thomas Earl Starzl, *Pittsburgh*
John H Stewart, *Winston-Salem*
Paul H Sugarbaker, *Washington*
Douglas S Tyler, *Durham*
Vic Velanovich, *Detroit*
Alan Wilkinson, *Los Angeles*
M Michael Wolfe, *Boston*
Christopher L Wolfgang, *Baltimore*
You-Min Wu, *Little Rock*
Zhi Zhong, *Charleston*



Contents

Monthly Volume 3 Number 3 March 27, 2011

EDITORIAL

- 31 Bowel endometriosis: Recent insights and unsolved problems
Ferrero S, Camerini G, Leone Roberti Maggiore U, Venturini PL, Biscaldi E, Remorgida V

CASE REPORT

- 39 A case report of extrahepatic portal vein aneurysm with thrombosis
Ishimura K, Otani T, Wakabayashi H, Okano K, Goda F, Suzuki Y

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastrointestinal Surgery*

APPENDIX I Meetings
I-V Instructions to authors

ABOUT COVER Ferrero S, Camerini G, Leone Roberti Maggiore U, Venturini PL, Biscaldi E, Remorgida V. Bowel endometriosis: Recent insights and unsolved problems
World J Gastrointest Surg 2011; 3(3): 31-38
<http://www.wjgnet.com/1948-9366/full/v3/i3/31.htm>

AIM AND SCOPE *World Journal of Gastrointestinal Surgery* (*World J Gastrointest Surg*, *WJGS*, online ISSN 1948-9366, DOI: 10.4240), is a monthly, open-access, peer-reviewed journal supported by an editorial board of 336 experts in gastrointestinal surgery from 35 countries.
The major task of *WJGS* is to rapidly report the most recent results in basic and clinical research on gastrointestinal surgery, specifically including micro-invasive surgery, laparoscopy, hepatic surgery, biliary surgery, pancreatic surgery, splenic surgery, surgical nutrition, portal hypertension, as well as the associated subjects such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, genetics, genomics, proteomics, pharmacology, pharmacokinetics, pharmacogenetics, molecular biology, clinical trials, diagnosis and therapeutics and multimodality treatment. Emphasis is placed on original research articles and clinical case reports. This journal will also provide balanced, extensive and timely review articles on selected topics.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Na Liu
Responsible Electronic Editor: Jin-Lei Wang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Jin-Lei Wang
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastrointestinal Surgery

LAUNCH DATE
November 30, 2009

SPONSOR
Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING
Editorial Board of *World Journal of Gastrointestinal Surgery*,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893
E-mail: wjgs@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING
Baishideng Publishing Group Co., Limited,
Room 1701, 17/F, Henan Building,
No.90 Jaffe Road, Wanchai,

Hong Kong, China
Fax: +852-3115-8812
Telephone: +852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION
Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
March 27, 2011

SERIAL PUBLICATION NUMBER
ISSN 1948-9366 (online)

PRESIDENT AND EDITOR-IN-CHIEF
Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF
Elijah Dixon, *Calgary*
Antonello Forgione, *Milan*
Tobias Keck, *Freiburg*
Tsuyoshi Konishi, *Tokyo*
Natale Di Martino, *Naples*

EDITORIAL OFFICE
Jin-Lei Wang, Director
World Journal of Gastrointestinal Surgery
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893
E-mail: wjgs@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT
© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/1948-9366/g_info_20100305152206.htm.

ONLINE SUBMISSION
<http://www.wjgnet.com/1948-9366office>

Bowel endometriosis: Recent insights and unsolved problems

Simone Ferrero, Giovanni Camerini, Umberto Leone Roberti Maggiore, Pier L Venturini, Ennio Biscaldi, Valentino Remorgida

Simone Ferrero, Umberto Leone Roberti Maggiore, Pier L Venturini, Valentino Remorgida, Department of Obstetrics and Gynecology, San Martino Hospital and University of Genoa, Largo R. Benzi 1, 16132 Genoa, Italy

Giovanni Camerini, Department of Surgery, San Martino Hospital and University of Genoa, Largo R. Benzi 1, 16132 Genoa, Italy

Ennio Biscaldi, Department of Radiology, Galliera Hospital, Via Mura delle Cappuccine 14, 16128 Genoa, Italy

Author contributions: All authors contributed to writing the manuscript.

Correspondence to: Ferrero Simone, MD, PhD, Department of Obstetrics and Gynecology, San Martino Hospital, Largo R. Benzi 1, 16132 Genoa, Italy. dr@simoneferrero.com

Telephone: +39-10-511525 Fax: +39-10-511525

Received: August 29, 2010 Revised: March 14, 2011

Accepted: March 21, 2011

Published online: March 27, 2011

Abstract

Bowel endometriosis affects between 3.8% and 37% of women with endometriosis. The evaluation of symptoms and clinical examination are inadequate for an accurate diagnosis of intestinal endometriosis. Transvaginal ultrasonography is the first line investigation in patients with suspected bowel endometriosis and allows accurate determination of the presence of the disease. Radiological techniques (such as magnetic resonance imaging and multidetector computerized tomography enteroclysis) are useful for estimating the extent of bowel endometriosis. Hormonal therapies (progestins, gonadotropin releasing hormone analogues and aromatase inhibitors) significantly improve pain and intestinal symptoms in patients with bowel stenosis less than 60% and who do not wish to conceive. However, hormonal therapies may not prevent the progression of bowel endometriosis and, therefore, patients receiving long-term treatment should be periodically monitored. Surgical excision of bowel endometriosis should be

offered to symptomatic patients with bowel stenosis greater than 60%. Intestinal endometriotic nodules may be excised by nodulectomy or segmental resection. Both surgical procedures improve pain, intestinal symptoms and fertility. Nodulectomy may be associated with a lower rate of complications.

© 2011 Baishideng. All rights reserved.

Key words: Bowel endometriosis; Diagnosis; Endometriosis; Gonadotropin releasing hormone analogue; Laparoscopy; Nodulectomy; Progestin; Colorectal resection

Peer reviewer: Imtiaz Ahmed Wani, PhD, Shodi Gali, Amira Kadal, Srinagar, India

Ferrero S, Camerini G, Leone Roberti Maggiore U, Venturini PL, Biscaldi E, Remorgida V. Bowel endometriosis: Recent insights and unsolved problems. *World J Gastrointest Surg* 2011; 3(3): 31-38 Available from: URL: <http://www.wjgnet.com/1948-9366/full/v3/i3/31.htm> DOI: <http://dx.doi.org/10.4240/wjgs.v3.i3.31>

INTRODUCTION

The term bowel endometriosis is used to indicate that endometrial-like gland and stroma infiltrate the intestinal wall reaching at least the subserous fat tissue and the subserous part of the enteric plexus^[1] (Figure 1). Endometriotic foci located on the bowel serosa should be considered peritoneal endometriosis and not intestinal endometriosis. The exact prevalence of bowel endometriosis in the general population is unknown, although it is estimated that it affects between 3.8% and 37% of women with endometriosis^[1]. The highest frequency of endometriotic nodules is on the sigmoid colon and the rectum, followed by the ileum, the appendix and the cecum^[1].

SYMPTOMS

Intestinal endometriotic lesions may have variable size and depth of infiltration in the bowel wall and they may, therefore, cause a wide range of symptoms. In addition, bowel nodules are associated with the presence of other endometriotic lesions in the pelvis in over 99% of patients^[2]. As a consequence, it may be difficult to determine whether intestinal endometriosis contributes to abdominal and pelvic pain. In general, small endometriotic lesions reaching only the subserosal fat tissue do not cause symptoms^[3]. Larger nodules infiltrating the intestinal muscular layer cause a wide range of symptoms including dyschezia, constipation, diarrhea, abdominal bloating, painful bowel movements, passage of mucus in the stools and cyclical rectal bleeding^[3,4]. The symptoms associated with intestinal endometriosis often mimic diarrhea-predominant or constipation-predominant irritable bowel syndrome^[5,6] and this differential diagnosis may be particularly challenging^[7]. It remains unclear how bowel endometriosis causes intestinal symptoms. Obviously, large endometriotic nodules may contain extensive fibrosis and thicken the bowel wall, resulting in a stenosis of the intestinal lumen (Figure 2) and perhaps mechanically hampering bowel transit. In addition, intestinal endometriotic lesions infiltrate and disrupt intestinal nervous plexus^[3], damage interstitial Cajal cells^[3], reduce the density of intestinal sympathetic nerve fibers^[8] and thus, cause an alteration in bowel physiology.

DIAGNOSIS

Both the evaluation of symptoms and clinical examination are inadequate for an accurate diagnosis of intestinal endometriosis^[9,10]. Therefore, ultrasonographic or radiological techniques are required to confirm this diagnosis before surgery^[11]. Although no gold standard is universally accepted for the diagnosis of bowel endometriosis, magnetic resonance imaging (MRI) is one of the techniques most commonly used (Figure 3). A study comprising 195 patients with suspected endometriosis demonstrated that MRI has a sensitivity of 88%, a specificity of 98%, a positive predictive value of 95%, a negative predictive value of 95%, and an accuracy of 95% in diagnosing intestinal endometriosis^[11]. These findings were subsequently confirmed by several other investigations^[9,10,12,13]. However, in some cases, the diagnosis of intestinal endometriosis by MRI may be difficult because nodules with small hemorrhagic content have a signal intensity very close to that of the surrounding muscular structures^[14]. Therefore, the injection of ultrasonography jelly in the vagina and the rectum during MRI has been proposed to facilitate the identification of intestinal lesions (Figure 4)^[15].

Several studies have demonstrated that transvaginal ultrasonography may not only accurately diagnose the presence of rectosigmoid endometriosis but it may also estimate the depth of infiltration of the nodules in the




Figure 1 Section of a bowel endometriotic nodule, hemeatoxylin eosin staining demonstrates the nodule infiltrate the mucosa.



Figure 2 Sections of an intestinal endometriotic nodule demonstrating the thickening of the bowel wall caused by the endometriotic nodule.



Figure 3 Magnetic resonance imaging, T2W sagittal image. A nodule infiltrating the rectum is well detectable (arrow). Enhancement of the nodule is observed after injection of iodinated contrast medium.

intestinal wall^[16-20]. However, it is well known that the diagnostic accuracy of ultrasonography depends on the experience of the operator. Adding water contrast to the rectum during transvaginal ultrasonography may facilitate not only the identification of intestinal endometriotic lesions but also the evaluation of the characteristics of the nodules (size, number, depth of infiltration in the intestinal wall, degree of stenosis of the intestinal lumen)^[21-23]



Figure 4 Magnetic resonance imaging enteroclysis. The rectosigmoid is distended by using 250-300 mL of ultrasonographic gel diluted with saline solution; the 20-Fr Foley catheter used for retrograde distension can be observed in the figure. The fluid solution has a biphasic behavior on MR sequences: hypointense in T1W images and hyperintense in T2W images. A small rectovaginal endometriotic nodule (larger diameter 12 mm) is observed (arrow).



Figure 5 Multidetector computerized tomography enteroclysis, coronal reconstruction. Endometriotic nodule infiltrating the muscularis propria of the sigmoid (shown by the arrowheads); the mucosa is not infiltrated.

However, bowel preparation is required before adding water contrast to the rectum.

Double-contrast barium enema has been widely used in the past and remains an accurate technique for the diagnosis of bowel endometriosis^[24-30]. Bowel nodules appear as extrinsic masses that are associated with mucosal fine crenulations^[26]. The value of this exam is limited by the fact that the degree of infiltration of endometriosis in the intestinal wall cannot be determined.

Multidetector computerized tomography enteroclysis (MDCT-e) has recently been suggested for the diagnosis of bowel endometriosis^[31,32]. After bowel preparation, retrograde colonic distension is performed on the computerized tomography bed by introducing about 2000 mL of water. During the enteroclysis, pharmacological inhibition of peristaltic waves is achieved by intravenous injection of hyoscine butylbromide. Patients are examined with a 16-row MDCT scanner in supine position; a volumetric acquisition is performed from the dome of the diaphragm to the pubic symphysis, in portal phase (40 s after the arterial peak) after the intravenous injection of



Figure 6 Multidetector computerized tomography enteroclysis, the arrow shows an endometriotic nodule infiltrating the ileum.

iodinated contrast medium. MDCT-e allows estimation not only of the presence of intestinal endometriosis but also of the characteristics of the nodules, in particular, the depth of infiltration of endometriosis in the intestinal wall. The infiltration of the intestinal serosa is characterized by the presence of small nodules adjacent to the bowel loop resulting in an irregular intestinal profile in these nodules, the fat plane between endometriosis and the bowel wall is preserved. When the muscularis propria is infiltrated, MDCT-e allows observation of the multilayered stratification of the thickened bowel wall. Full thickness infiltration of the bowel wall is diagnosed when the solid nodules infiltrate the submucosa (which appears as a hypodense layer between the lumen and the muscularis propria) reaching the intestinal mucosa (Figure 5)^[31,32]. A strength of MDCT-e is that it allows detection of endometriotic lesions in the cecum and lower ileal loops which might be undiagnosed by other exams (Figure 6). The major disadvantages of MDCT-e are the use of iodinated contrast medium and ionizing radiations.

Rectal endoscopic ultrasonography has been widely used for the diagnosis of intestinal endometriosis^[12,33-34]. This exam permits to estimation of the precise depth of infiltration of endometriosis in the intestinal wall (in particular, the infiltration of the muscularis propria), the maximum diameter of the lesions and the distance of the lesions from the anus^[1]. In the last few years, rectal endoscopic ultrasonography has been largely replaced by transvaginal ultrasonography which is better tolerated by the patients. In addition, the equipment for performing rectal endoscopic ultrasonography is often unavailable to gynecologists, the clinicians who are commonly involved in the diagnosis and management of endometriosis.

Colonoscopy has limited value in the diagnosis of intestinal endometriosis because the disease infiltrates the intestinal wall from the serosa toward the mucosa and, therefore, only large nodules infiltrating the mucosa and/or causing a severe stenosis of the intestinal lumen can be diagnosed during this type of exam^[1]. In rare cases, colonoscopy may be used to exclude the presence of colorectal cancer.

MANAGEMENT OF BOWEL ENDOMETRIOSIS

The management strategy for bowel endometriosis depends on the size of the nodule, the degree of stenosis of the intestinal lumen and the symptoms experienced by the patients. In a small percentage of women, intestinal endometriotic lesions do not cause symptoms and, therefore, these patients may not receive treatment. However, in these patients, the thickening of the bowel lumen (leading to intestinal stenosis) should be evaluated in order to exclude the risk of bowel occlusion. Larger endometriotic nodules causing intestinal symptoms may be treated by hormonal therapy or by surgery.

MEDICAL TREATMENT OF BOWEL ENDOMETRIOSIS

Hormonal therapy cannot be offered to all women with intestinal endometriosis. Patients with intestinal nodules causing a bowel stenosis and those wishing to conceive are not good candidates for long-term endocrine therapy, which inhibits ovulation. The available ultrasonographic and radiological techniques allow accurate estimation of the presence, number and depth of infiltration of intestinal endometriotic lesions; hormonal therapy may be safely offered to women with estimated bowel stenosis of < 60%.

Hormonal therapies commonly used to treat pelvic endometriosis can generally be prescribed to women with bowel endometriosis. In the past, gonadotropin-releasing hormone analogues (GnRH-a) have occasionally been used to treat patients with bowel endometriosis^[35]. However, most authors simply report the recurrence of pain symptoms when the therapy with GnRH-a was discontinued^[36,37]. In one case report, the disappearance of an intestinal endometriotic polyp was reported after 3-mo treatment with GnRH-a^[38]. More recently, a prospective study systematically investigated the effects of a 12-mo treatment with triptorelin and tibolone on pain and intestinal symptoms in 18 women with colorectal endometriotic nodules^[39]. As expected, the treatment improved pain symptoms. In addition, it significantly reduced the severity of symptoms mimicking diarrhea-predominant irritable bowel syndrome, intestinal cramping, abdominal bloating and passage of mucus with stools. On the contrary, seven women with symptoms mimicking constipation-predominant irritable bowel syndrome reported only minor changes in their intestinal symptoms^[39].

Progestins are among the most commonly used medical treatments for endometriosis. Several studies have proved that these agents effectively reduce the severity of symptoms caused by pelvic endometriosis and are in general well tolerated^[40]. One prospective study examined the effects of progestins on the symptoms caused by intestinal endometriosis^[41]. Forty symptomatic women with colorectal endometriosis were treated with norethisterone acetate (2.5 mg/d) for 12 mo. This reduced the severity of chronic




Figure 7 Nodulectomy, the endometriotic nodule is shown by the asterisk.

pelvic pain, deep dyspareunia and dyschezia. As expected, the treatment resulted in the disappearance of symptoms related to the menstrual cycle such as dysmenorrhea, constipation during the menstrual cycle, diarrhea during the menstrual cycle and cyclical rectal bleeding. The severity of diarrhea, intestinal cramping and passage of mucus significantly improved during treatment. However, the administration of norethisterone acetate did not produce a significant effect on constipation, abdominal bloating and feeling of incomplete evacuation after bowel movements. More recently, aromatase inhibitors have been suggested for the treatment of endometriosis^[42]. A prospective pilot study comprising six women with colorectal endometriosis demonstrated that pain and intestinal symptoms are improved by the combined administration of an aromatase inhibitor (letrozole, 2.5 mg/d) and norethisterone acetate (2.5 mg/d) continuously for 6 mo^[43].

Although hormonal therapies may improve the symptoms caused by intestinal endometriosis, the natural history of bowel nodules is not established. It is well known that patients undergoing surgery because of extensive intestinal endometriotic lesions have often used hormonal therapies for years. Therefore, it is possible that hormonal therapies, despite improving symptoms, do not prevent the development or progression of intestinal endometriosis. A recent report described the case of a woman with a diagnosis of an endometriotic serosal sigmoid nodule at MDCT-e which enlarged after 41 mo of continuous oral contraceptive pill, infiltrating the bowel submucosa and requiring segmental bowel resection^[44]. Therefore, patients using long-term hormonal therapies to treat intestinal endometriosis should be carefully monitored by using transvaginal ultrasonography or MRI in order to identify the potential progression of intestinal nodules. In addition, these patients should be informed that the progression of the disease might occur despite the improvement in pain symptoms.

SURGICAL TREATMENT OF BOWEL ENDOMETRIOSIS

Small endometriotic lesions infiltrating only the intestinal




Figure 8 A mechanic circular stapler inserted transrectally is used to perform an end-to-end anastomosis.

serosa or the adventitia are unlikely to cause symptoms and may, therefore, not be excised. However, they can be easily removed by cutting the normal bowel wall adjacent to the lesion with scissors or CO₂ laser. The defect of the intestinal wall can then be repaired by interrupted suture.

Larger colorectal endometriotic nodules infiltrating the intestinal muscularis propria can be excised by either nodulectomy (partial or full thickness) (Figure 7) or segmental bowel resection. The choice of the surgical technique is based partly on the characteristics of the intestinal lesions such as, number of nodules, size of the nodules, depth of infiltration of the intestinal wall and percentage of the intestinal circumference infiltrated by endometriosis. However, surgeon's experience and preferences also influence the decision to perform either bowel segmental resection or nodulectomy.

Colorectal resection which is a standardized surgical procedure that has been used for decades for the treat-

ment of sigmoid or rectal cancer is similarly performed (most often by laparoscopy) in women with endometriosis. The endometriotic nodule is separated from the adherent tissues, but no attempt is made to separate the nodule from the bowel. Bowel preparation requires opening the pararectal spaces in order to mobilize the bowel. As endometriosis is not a malignant disease, the separation of the fibrofatty tissue attached to the bowel is best performed immediately adjacent to the bowel wall because the vessels are smaller and easier to coagulate. The mesentery is dissected no more than 2 cm past the endometriotic lesions in order to maintain adequate blood supply to the edges of the anastomosis^[1]. After the bowel is resected caudal to the endometriotic lesion by using Endo GIA, the proximal portion of the bowel is extracted through a small supra-pubic incision. After accurate inspection and palpation, the bowel segment infiltrated by endometriosis is resected. The anvil of a transanal circular stapler is inserted into the proximal bowel stump and fixed by a purse-string suture. An end-to-end anastomosis is performed transrectally using a mechanic circular stapler (Figure 8). After completing the anastomosis, the possible presence of leaks must always be checked. In patients with endometriosis, the most important argument in favor of segmental bowel resection is the fact that this technique allows a more radical removal of intestinal endometriotic foci, thus minimizing the risk of recurrences. Over the last 10 years, several studies have showed that, in women with colorectal endometriosis, segmental bowel resection improves pain, intestinal symptoms and quality of life^[12,45-48]. However, segmental resection may be associated with several complications including urinary retention, inadvertent ureteral lesions, anastomosis leakage and fecal peritonitis, recto-vaginal fistulas, anastomotic stenosis, pelvic abscesses and postoperative constipation^[1,30,46]. Segmental bowel resection can be performed either by laparoscopy or by laparotomy. During segmental colorectal resection because of bowel endometriosis, the reported conversion rates from laparoscopy to laparotomy range from 0% to 20%^[49,50]. A recent randomized trial comparing laparoscopic and open colorectal resection for endometriosis demonstrated that the two surgical techniques result in a similar improvement in symptoms and quality of life^[49]. However, blood loss, analgesic consumption and complication rate were higher in patients undergoing open surgery than in those undergoing laparoscopy^[49].

It is currently debated whether bowel endometriosis should be removed by segmental resection or by nodulectomy. A prospective surgical and histological study evaluated the completeness of full thickness disk resection^[46]. In 16 women requiring segmental bowel resection, nodulectomy was performed before segmental resection. In 7 out of 16 cases (43.8%), endometriosis was still present in the muscularis propria adjacent to the site of nodulectomy. A similar rate of persistent disease was observed after laparoscopic and laparotomic full thickness disk resection^[51]. However, the clinical implications of these observations remain unclear because it seems unlikely that

small endometriotic lesions will cause symptoms or progress to large intestinal nodules. In addition, in segmental resection, persistence of endometriosis may also be observed at the margin of the resected intestinal segment^[51]. A recent study of 500 women with deep endometriosis and rectal muscularis involvement demonstrated that, after laparoscopic nodulectomy, symptoms recurred only in 8% of the patients after a median follow-up of 3.1 years^[30]. In addition, the recurrence of symptoms was significantly lower in patients who conceived after surgery than in those who did not conceive^[30]. When compared with segmental bowel resection, nodulectomy may have the advantage of a lower incidence of postoperative unpleasant functional digestive outcomes (such as increase in the daily number of stools, severe postoperative constipation and urinary dysfunction)^[52]. In fact, during nodulectomy, nerves and vascular blood supply are preserved because it is not necessary to perform the deep lateral dissection that is required during segmental resection^[30,52]. Similarly, after segmental bowel resection, the full recovery of gastrointestinal function can usually be observed several months after surgery^[53].

FERTILITY AFTER SURGERY FOR BOWEL ENDOMETRIOSIS

Several studies have showed that good pregnancy rates are achieved after surgical excision of intestinal endometriosis. A retrospective study of 22 women wishing to conceive reported a 45.5% pregnancy rate after a mean follow-up of 24 mo from laparoscopic colorectal resection^[54]. Subsequently, a prospective cohort study of 46 symptomatic women undergoing colorectal resection because of endometriosis showed that the pregnancy rate was significantly higher after laparoscopic (57.6%) than after laparotomic procedures (23.1%)^[55]. More recently, a study of 288 women wishing to conceive demonstrated that nodulectomy is associated with an 84% pregnancy rate (obtained either naturally or after assisted reproductive technologies) after a median follow-up of 3.1 years^[30].

CONCLUSION

The symptoms of bowel endometriosis are not specific, therefore its presence should be suspected in all women with endometriosis who complain of intestinal symptoms. Transvaginal ultrasonography is the first line investigation for patients with suspected bowel endometriosis as it allows to accurate determination of the presence of the disease^[19,20,22]. Additional radiological techniques (such as MRI and MDCT-e) are useful to determine the extent of intestinal endometriotic lesions^[11,31].

The management of bowel endometriosis depends on the severity of symptoms, the extent of the disease, the desire of the patient to conceive and the tolerability of hormonal therapies. Progestins and gonadotropin releasing hormone analogues may be offered to women with

stenosis of the bowel lumen < 60% who wish to avoid surgery and do not desire to conceive^[39,41]. However, hormonal therapies may not prevent the progression of bowel endometriosis^[44] and, therefore, patients receiving long-term treatment should be periodically monitored.

The decision to carry out surgery should be undertaken in selected patients, such as those who are highly symptomatic, have a severe stenosis of the intestinal lumen or cannot use hormonal therapies because of the desire to conceive. Intestinal endometriotic lesions can be excised by either segmental resection or nodulectomy; it remains to be established whether one surgical technique is superior to the other. However, before surgery patients should be fully informed of potential complications including the time required to obtain a full recovery of the digestive function.

REFERENCES

- 1 **Remorgida V**, Ferrero S, Fulcheri E, Ragni N, Martin DC. Bowel endometriosis: presentation, diagnosis, and treatment. *Obstet Gynecol Surv* 2007; **62**: 461-470
- 2 **Redwine DB**. Ovarian endometriosis: a marker for more extensive pelvic and intestinal disease. *Fertil Steril* 1999; **72**: 310-315
- 3 **Remorgida V**, Ragni N, Ferrero S, Anserini P, Torelli P, Fulcheri E. The involvement of the interstitial Cajal cells and the enteric nervous system in bowel endometriosis. *Hum Reprod* 2005; **20**: 264-271
- 4 **Seracchioli R**, Mabrouk M, Guerrini M, Manuzzi L, Savelli L, Frasca C, Venturoli S. Dyschezia and posterior deep infiltrating endometriosis: analysis of 360 cases. *J Minim Invasive Gynecol* 2008; **15**: 695-699
- 5 **Ferrero S**, Abbamonte LH, Remorgida V, Ragni N. Irritable bowel syndrome and endometriosis. *Eur J Gastroenterol Hepatol* 2005; **17**: 687
- 6 **Ferrero S**, Abbamonte LH, Valentino R, Ragni N. Abdominal pain, bloating, and urgency. *Obstet Gynecol* 2005; **106**: 195; author reply 195
- 7 **Ferrero S**, Camerini G, Ragni N, Remorgida V. Endometriosis and irritable bowel syndrome: co-morbidity or misdiagnosis? *BJOG* 2009; **116**: 129; author reply 129-130
- 8 **Ferrero S**, Haas S, Remorgida V, Camerini G, Fulcheri E, Ragni N, Straub RH, Capellino S. Loss of sympathetic nerve fibers in intestinal endometriosis. *Fertil Steril* 2010; **94**: 2817-2819
- 9 **Abrao MS**, Gonçalves MO, Dias JA Jr, Podgaec S, Chamie LP, Blasbalg R. Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis. *Hum Reprod* 2007; **22**: 3092-3097
- 10 **Bazot M**, Lafont C, Rouzier R, Roseau G, Thomassin-Naggara I, Daraï E. Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. *Fertil Steril* 2009; **92**: 1825-1833
- 11 **Bazot M**, Daraï E, Hourani R, Thomassin I, Cortez A, Uzan S, Buy JN. Deep pelvic endometriosis: MR imaging for diagnosis and prediction of extension of disease. *Radiology* 2004; **232**: 379-389
- 12 **Chapron C**, Vieira M, Chopin N, Balleyguier C, Barakat H, Dumontier I, Roseau G, Fauconnier A, Foulot H, Dousset B. Accuracy of rectal endoscopic ultrasonography and magnetic

- resonance imaging in the diagnosis of rectal involvement for patients presenting with deeply infiltrating endometriosis. *Ultrasound Obstet Gynecol* 2004; **24**: 175-179
- 13 **Chamié LP**, Blasbalg R, Gonçalves MO, Carvalho FM, Abrão MS, de Oliveira IS. Accuracy of magnetic resonance imaging for diagnosis and preoperative assessment of deeply infiltrating endometriosis. *Int J Gynaecol Obstet* 2009; **106**: 198-201
 - 14 **Biscaldi E**, Ferrero S, Remorgida V, Fulcheri E, Rollandi GA. Rectosigmoid endometriosis with unusual presentation at magnetic resonance imaging. *Fertil Steril* 2009; **91**: 278-280
 - 15 **Loubeyre P**, Petignat P, Jacob S, Egger JF, Dubuisson JB, Wenger JM. Anatomic distribution of posterior deeply infiltrating endometriosis on MRI after vaginal and rectal gel opacification. *AJR Am J Roentgenol* 2009; **192**: 1625-1631
 - 16 **Bazot M**, Thomassin I, Hourani R, Cortez A, Darai E. Diagnostic accuracy of transvaginal sonography for deep pelvic endometriosis. *Ultrasound Obstet Gynecol* 2004; **24**: 180-185
 - 17 **Bazot M**, Malzy P, Cortez A, Roseau G, Amouyal P, Darai E. Accuracy of transvaginal sonography and rectal endoscopic sonography in the diagnosis of deep infiltrating endometriosis. *Ultrasound Obstet Gynecol* 2007; **30**: 994-1001
 - 18 **Piketty M**, Chopin N, Dousset B, Millischer-Bellaische AE, Roseau G, Leconte M, Borghese B, Chapron C. Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal ultrasonography must definitely be the first-line imaging examination. *Hum Reprod* 2009; **24**: 602-607
 - 19 **Hudelist G**, Tuttlies F, Rauter G, Pucher S, Keckstein J. Can transvaginal sonography predict infiltration depth in patients with deep infiltrating endometriosis of the rectum? *Hum Reprod* 2009; **24**: 1012-1017
 - 20 **Goncalves MO**, Podgaec S, Dias JA Jr, Gonzalez M, Abrao MS. Transvaginal ultrasonography with bowel preparation is able to predict the number of lesions and rectosigmoid layers affected in cases of deep endometriosis, defining surgical strategy. *Hum Reprod* 2010; **25**: 665-671
 - 21 **Menada MV**, Remorgida V, Abbamonte LH, Fulcheri E, Ragni N, Ferrero S. Transvaginal ultrasonography combined with water-contrast in the rectum in the diagnosis of rectovaginal endometriosis infiltrating the bowel. *Fertil Steril* 2008; **89**: 699-700
 - 22 **Valenzano Menada M**, Remorgida V, Abbamonte LH, Nicoletti A, Ragni N, Ferrero S. Does transvaginal ultrasonography combined with water-contrast in the rectum aid in the diagnosis of rectovaginal endometriosis infiltrating the bowel? *Hum Reprod* 2008; **23**: 1069-1075
 - 23 **Morotti M**, Ferrero S, Bogliolo S, Venturini PL, Remorgida V, Valenzano Menada M. Transvaginal ultrasonography with water-contrast in the rectum in the diagnosis of bowel endometriosis. *Minerva Ginecol* 2010; **62**: 179-185
 - 24 **Gordon RL**, Evers K, Kressel HY, Laufer I, Herlinger H, Thompson JJ. Double-contrast enema in pelvic endometriosis. *AJR Am J Roentgenol* 1982; **138**: 549-552
 - 25 **Squifflet J**, Feger C, Donnez J. Diagnosis and imaging of adenomyotic disease of the retroperitoneal space. *Gynecol Obstet Invest* 2002; **54** Suppl 1: 43-51
 - 26 **Landi S**, Barbieri F, Fiaccavento A, Mainardi P, Ruffo G, Selvaggi L, Syed R, Minelli L. Preoperative double-contrast barium enema in patients with suspected intestinal endometriosis. *J Am Assoc Gynecol Laparosc* 2004; **11**: 223-228
 - 27 **Faccioli N**, Manfredi R, Mainardi P, Dalla Chiara E, Spoto E, Minelli L, Mucelli RP. Barium enema evaluation of colonic involvement in endometriosis. *AJR Am J Roentgenol* 2008; **190**: 1050-1054
 - 28 **Ribeiro HS**, Ribeiro PA, Rossini L, Rodrigues FC, Donadio N, Aoki T. Double-contrast barium enema and transrectal endoscopic ultrasonography in the diagnosis of intestinal deeply infiltrating endometriosis. *J Minim Invasive Gynecol* 2008; **15**: 315-320
 - 29 **Faccioli N**, Foti G, Manfredi R, Mainardi P, Spoto E, Ruffo G, Minelli L, Mucelli RP. Evaluation of colonic involvement in endometriosis: double-contrast barium enema vs. magnetic resonance imaging. *Abdom Imaging* 2010; **35**: 414-421
 - 30 **Donnez J**, Squifflet J. Complications, pregnancy and recurrence in a prospective series of 500 patients operated on by the shaving technique for deep rectovaginal endometriotic nodules. *Hum Reprod* 2010; **25**: 1949-1958
 - 31 **Biscaldi E**, Ferrero S, Fulcheri E, Ragni N, Remorgida V, Rollandi GA. Multislice CT enteroclysis in the diagnosis of bowel endometriosis. *Eur Radiol* 2007; **17**: 211-219
 - 32 **Biscaldi E**, Ferrero S, Remorgida V, Rollandi GA. Bowel endometriosis: CT-enteroclysis. *Abdom Imaging* 2007; **32**: 441-450
 - 33 **Chapron C**, Dumontier I, Dousset B, Fritel X, Tardif D, Roseau G, Chaussade S, Couturier D, Dubuisson JB. Results and role of rectal endoscopic ultrasonography for patients with deep pelvic endometriosis. *Hum Reprod* 1998; **13**: 2266-2270
 - 34 **Bazot M**, Detchev R, Cortez A, Amouyal P, Uzan S, Darai E. Transvaginal sonography and rectal endoscopic sonography for the assessment of pelvic endometriosis: a preliminary comparison. *Hum Reprod* 2003; **18**: 1686-1692
 - 35 **Markham SM**, Welling DR, Larsen KS, Snell MJ. Endometriosis of the rectum treated with a long term GnRH agonist and surgery. *N Y State J Med* 1991; **91**: 69-71
 - 36 **Verspyck E**, Lefranc JP, Guyard B, Blondon J. Treatment of bowel endometriosis: a report of six cases of colorectal endometriosis and a survey of the literature. *Eur J Obstet Gynecol Reprod Biol* 1997; **71**: 81-84
 - 37 **Thomassin I**, Bazot M, Detchev R, Barranger E, Cortez A, Darai E. Symptoms before and after surgical removal of colorectal endometriosis that are assessed by magnetic resonance imaging and rectal endoscopic sonography. *Am J Obstet Gynecol* 2004; **190**: 1264-1271
 - 38 **Porpora MG**, Pallante D, Ferro A, Crobu M, Cerenzia P, Panici PL. Intestinal endometriosis without evident pelvic foci treated with gonadotropin-releasing hormone agonist. *Eur J Obstet Gynecol Reprod Biol* 2006; **125**: 265-266
 - 39 **Ferrero S**, Camerini G, Ragni N, Menada MV, Venturini PL, Remorgida V. Triptorelin improves intestinal symptoms among patients with colorectal endometriosis. *Int J Gynaecol Obstet* 2010; **108**: 250-251
 - 40 **Ferrero S**, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. *Expert Opin Pharmacother* 2010; **11**: 1123-1134
 - 41 **Ferrero S**, Camerini G, Ragni N, Venturini PL, Biscaldi E, Remorgida V. Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. *Hum Reprod* 2010; **25**: 94-100
 - 42 **Ferrero S**, Venturini PL, Ragni N, Camerini G, Remorgida V. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. *Drugs* 2009; **69**: 943-952
 - 43 **Ferrero S**, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, Remorgida V. Letrozole and norethisterone acetate in colorectal endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2010; **150**: 199-202
 - 44 **Ferrero S**, Camerini G, Venturini PL, Biscaldi E, Remorgida V. Progression of bowel endometriosis during treatment with the oral contraceptive pill. *Gynecol Surg* 2010; Epub ahead of print
 - 45 **Dubernard G**, Piketty M, Rouzier R, Houry S, Bazot M, Darai E. Quality of life after laparoscopic colorectal resection for endometriosis. *Hum Reprod* 2006; **21**: 1243-1247
 - 46 **Seracchioli R**, Poggiali G, Pierangeli F, Manuzzi L, Gualerzi B, Savelli L, Remorgida V, Mabrouk M, Venturoli S. Surgical

- outcome and long-term follow up after laparoscopic rectosigmoid resection in women with deep infiltrating endometriosis. *BJOG* 2007; **114**: 889-895
- 47 **Minelli L**, Fanfani F, Fagotti A, Ruffo G, Ceccaroni M, Mereu L, Landi S, Pomini P, Scambia G. Laparoscopic colorectal resection for bowel endometriosis: feasibility, complications, and clinical outcome. *Arch Surg* 2009; **144**: 234-239; discussion 239
 - 48 **Ferrero S**, Camerini G, Menada MV, Biscaldi E, Ragni N, Remorgida V. Uterine adenomyosis in persistence of dysmenorrhea after surgical excision of pelvic endometriosis and colorectal resection. *J Reprod Med* 2009; **54**: 366-372
 - 49 **Daraï E**, Dubernard G, Coutant C, Frey C, Rouzier R, Ballester M. Randomized trial of laparoscopically assisted versus open colorectal resection for endometriosis: morbidity, symptoms, quality of life, and fertility. *Ann Surg* 2010; **251**: 1018-1023
 - 50 **Daraï E**, Bazot M, Rouzier R, Houry S, Dubernard G. Outcome of laparoscopic colorectal resection for endometriosis. *Curr Opin Obstet Gynecol* 2007; **19**: 308-313
 - 51 **Remorgida V**, Ragni N, Ferrero S, Anserini P, Torelli P, Fulcheri E. How complete is full thickness disc resection of bowel endometriotic lesions? A prospective surgical and histological study. *Hum Reprod* 2005; **20**: 2317-2320
 - 52 **Roman H**, Loisel C, Resch B, Tuech JJ, Hochain P, Leroi AM, Marpeau L. Delayed functional outcomes associated with surgical management of deep rectovaginal endometriosis with rectal involvement: giving patients an informed choice. *Hum Reprod* 2010; **25**: 890-899
 - 53 **Ferrero S**, Ragni N, Remorgida V. Post-operative digestive symptoms after colorectal resection for endometriosis. *Hum Reprod* 2006; **21**: 1941-1942; author reply 1942-1943
 - 54 **Daraï E**, Marpeau O, Thomassin I, Dubernard G, Barranger E, Bazot M. Fertility after laparoscopic colorectal resection for endometriosis: preliminary results. *Fertil Steril* 2005; **84**: 945-950
 - 55 **Ferrero S**, Anserini P, Abbamonte LH, Ragni N, Camerini G, Remorgida V. Fertility after bowel resection for endometriosis. *Fertil Steril* 2009; **92**: 41-46

S- Editor Wang JL **L- Editor** Hughes D **E- Editor** Zheng XM

A case report of extrahepatic portal vein aneurysm with thrombosis

Ken Ishimura, Tsuyoshi Otani, Hisao Wakabayashi, Keiichi Okano, Fuminori Goda, Yasuyuki Suzuki

Ken Ishimura, Tsuyoshi Otani, Hisao Wakabayashi, Department of Surgery, Kagawakensaiseikai Hospital, 1331-1 Tahikami, Takamatsu, Kagawa, 761-8076, Japan

Keiichi Okano, Fuminori Goda, Yasuyuki Suzuki, Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, 1750-1 Miki, Kagawa, 761-0793, Japan

Author contributions: Ishimura K, Otani T, Wakabayashi H, Okano K, Goda F and Suzuki Y designed and performed research; Ishimura K wrote the paper.

Correspondence to: Ken Ishimura, MD, Department of Surgery, Kagawakensaiseikai Hospital, 1331-1 Tahikami, Takamatsu, Kagawa, 761-8076, Japan. ishimura@kms.ac.jp
Telephone: +81-87-8681551 Fax: +81-87-8689733

Received: February 21, 2010 Revised: November 29, 2010

Accepted: December 6, 2010

Published online: March 27, 2011

Peer reviewers: Robert Chamuleau, MD, PhD, Department of Hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 69-71, Building S, Floor 1, Room 133, 1105 BK Amsterdam, The Netherlands; Marcelo AF Ribeiro, MD, PhD, TCBC, TCBCD, FACS, Department of Surgery, Santo Amaro University, Alameda Gregorio Bogossian Sobrinho, 80 /155, Santana de Parnaíba, SP 06543-385, Brazil

Ishimura K, Otani T, Wakabayashi H, Okano K, Goda F, Suzuki Y. A case report of extrahepatic portal vein aneurysm with thrombosis. *World J Gastrointest Surg* 2011; 3(3): 39-42 Available from: URL: <http://www.wjgnet.com/1948-9366/full/v3/i3/39.htm> DOI: <http://dx.doi.org/10.4240/wjgs.v3.i3.39>

Abstract

Extrahepatic portal vein aneurysm (PVA) is very rare with only 17 previously reported cases. Methods of treatment include resection, thrombectomy, and portal venous decompression. We report herein the first case of large PVA with thrombosis which has been managed without surgical treatment over a long period. A PVA was detected in a 78-year-old woman by abdominal ultrasonography. Computed tomography revealed an aneurysm of 6 cm in a diameter in the porta hepatis. Portal venography showed obstruction of the portal vein and developed collateral vessels around the aneurysm. Since the patient had no symptoms of portal hypertension, we decided to carefully manage her clinical course without surgical treatment. At present, this patient is healthy and has developed no complications over the 5 years since leaving our hospital. This case suggests that surgical treatment is not required for PVA without portal hypertension.

© 2011 Baishideng. All rights reserved.

Key words: Portal vein aneurysm; Thrombosis; Surgical treatment

INTRODUCTION

Portal vein aneurysm (PVA) is a very rare venous malformation. Barzilai *et al*^[1] reported the first case of PVA in 1956. To our knowledge, only 17 proven cases of extrahepatic PVA have previously been reported in the English language, worldwide^[1-16]. The etiology of PVA is unknown due to its rarity. PVA is thought to be either of congenital origin, caused by hypoplasia or atresia of the portal vein, or acquired as a result of portal hypertension or trauma. Methods of PVA management include observation, resection, thrombectomy, and portal venous decompression. We report herein a case of large PVA with thrombosis that has been managed without surgical treatment in a long-term.

CASE REPORT

A 78-year-old woman was admitted to our surgical department with a PVA. Her chief complaint was abdominal discomfort. The patient had no history of abdominal surgery, liver biopsy, trauma, or hepatitis. She had already been diagnosed 6 years previously at another medical institution with an aneurysm of 3 cm in a diameter located in the main portal trunk. However, she had not under-

Table 1 Reported extrahepatic portal vein aneurysms

Author (year)	Age (yr)	Sex	Size(cm)	Liver disease	Portal hypertension	Treatment
Barzilai <i>et al</i> ^[1] (1956)	21	F	2	Liver cirrhosis	+	Splenectomy
Leonsins <i>et al</i> ^[2] (1960)	52	M	8	Liver cirrhosis	+	Splenectomy
Sedgwick ^[3] (1960)	25	F	5	Liver cirrhosis	+	Cholecystojejunostomy
Hermann <i>et al</i> ^[4] (1965)	26	F	6	Portal fibrosis	+	Portocaval shunt
Liebowitz <i>et al</i> ^[5] (1967)	55	F	8	-	-	Splenectomy
Thomas ^[6] (1967)	18	M	8	Obstructive jaundice	+	Died
Thomas <i>et al</i> ^[6] (1967)	13	F	3	-	+	Portocaval shunt
Vine <i>et al</i> ^[7] (1979)	50	F	3	Hepatic parenchymal abnormality	-	Observation
Boyez <i>et al</i> ^[8] (1986)	57	F	4	-	-	Observation
Thompson <i>et al</i> ^[9] (1986)	21	F	6	-	-	Cholecystectomy
Andoh <i>et al</i> ^[10] (1988)	57	F	8	-	-	Partial resection PVA
Lee <i>et al</i> ^[11] (1989)	5	M	1.9	-	-	Splenectomy
Baker <i>et al</i> ^[12] (1990)	34	F	8	-	-	Observation
Hagiwara <i>et al</i> ^[13] (1991)	34	M	2.7	-	-	Resection PVA
Dognini <i>et al</i> ^[14] (1991)	67	F	2.4	-	-	Splenectomy
Glazer <i>et al</i> ^[15] (1991)	26	F	7	-	+	Observation
Brock <i>et al</i> ^[16] (1997)	72	F	6	-	-	Sphincterotomy
Present case	78	F	6	-	-	Thrombectomy
						Aneurysmorrhaphy
						Resection PVA
						Observation



Figure 1 Ultrasound oblique scan through the long axis of the portal vein.

gone further examination until this hospitalization. On admission, the patient was 137 cm in height and weighed 40 kg, having exhibited no weight loss. Her consciousness was alert. Results of a general physical examination were otherwise normal; the palpebral conjunctiva was not anemic and the bulbar conjunctiva was not icteric. The liver and spleen were not palpable, and the abdomen was soft and flat, with no palpable tumor. No vascular bruit was heard. Laboratory test results included aspartate transaminase of 22 U/L, alanine transaminase of 63 U/L, and alkaline phosphatase of 430 U/L. Abdominal ultrasonogram showed a hypoechoic mass connected with the main portal trunk (Figure 1). Computed tomography scan revealed a mass of 6 cm in a diameter in the porta hepatis (Figure 2A). Developed collateral vessels around the mass were detected on the delay phase by intravenous contrast material, suggesting thrombosis of the portal aneurysm (Figure 2B). The venous phase of a superior mesenteric artery angiogram showed obstruction of the

portal vein, and that intrahepatic portal flow was maintained by collateral supply (Figure 3). There was no arterial or venous fistula. As the patient's liver function was almost within normal limits and she showed no symptoms of portal hypertension, we decided not to intervene surgically but to carefully monitor her clinical course. She was well when discharged, and has remained symptom-free for 5 years since leaving the hospital.

DISCUSSION

Since the natural history of PVA is not clear, it is difficult to determine the strategy of treatment for this disease.

The 18 reported cases of extrahepatic PVA, including our case^[1-16], are listed in Table 1. The age of patients in these cases varies from 5 to 78 years old, with our patient being oldest. The PVA ranged from 1.9 to 8 cm in a diameter, with an average diameter of 5.3 cm. Six of the 18 cases revealed underlying liver disease^[1-4,6,7], and seven were associated with portal hypertension^[1-4,6,15]. The advance of radiological diagnosis has resulted in the identification of a number of PVA without liver disease since 1986. Surgical treatments were performed on 13 out of the 18 cases, and direct surgery for PVA was carried out in four^[10,12,15,16]. Resection of PVA was done in three cases, and thrombectomy and aneurysmorrhaphy were performed on one case with thrombus. On the other hand, five cases including our case, were managed by observation^[7,8,11,13]. A PVA of 4 cm in diameter monitored for 2 years did not change in size^[8] and aneurysms reported by Lee and Hagiwara did not change in size after 5 years of observation^[11,13]. These aneurysms were smaller than the one observed in our patient.

Excluding our case, three out of 17 patients had throm-




Figure 2 Abdominal computed tomography scan with contrast. A: A hypovascular mass in the porta hepatis; B: Developed collateral vessels around the mass.

bus^[1,6,15]. Two of these died of aneurysm rupture^[1,6]. Both were less than 30 years old. Their PVA etiology seemed to be acquired, as their PVA was the result of liver disease. On the other hand, the remaining patient was treated by a surgical procedure, and remained symptom free for 10 years after operation^[15]. The origin of this case was also acquired. However it is unclear whether operation was needed in this case, given that the PVA contained a large amount of organized clot and the wall of the aneurysm showed normal venous structure with no atrophy of the muscle. Our patient had chronic progress, and PVA etiology was suspected to be of congenital origin. She was saved from rupture of the PVA as collateral vessels had developed around it. We inferred that the patient was symptom free because of the formation of sufficient collaterals. We believe that after short follow-up asymptomatic aneurysm with thrombus can be successfully managed by observation alone.

The decision on surgical treatment depends on the size, anatomy of PVA as well as the symptoms and condition of the patient. In the past, large PVAs over 4 cm in diameter had been operated on. Ours seems to be the first case reported without operative treatment for PVAs over 5 cm in a diameter. Miyauchi *et al.*^[17] concluded that the indications for surgical interventions in the treatment of PVA with porta hepatic venous fistula were as follows: (1) Patients with symptoms and large shunts; (2) Patients with enlarging fistulae; and (3) Patients with multiple fistulae where angiography shows that the lesions are sufficiently




Figure 3 Portal venogram (digital subtraction angiogram) after selective superior mesenteric arteriography.

localized that the volume of the shunt cannot be reduced by conservative therapy. Moreover, patients who have biliary tract obstruction and hemobilia caused by PVAs also require operation.

Since the natural history and incidence of PVA is not well known, it is difficult to decide the best treatment. Prognosis in symptomatic patients treated with surgery is dependent on the underlying liver disease. In a case reported by Brock, the patient underwent PVA resection because of a lack of experience for judging whether the large uncomplicated saccular PVA in his patient should be resected^[16]. However, our case indicated a natural history of PVA without arterial or venous fistula, and suggests that surgical treatment is not required for PVA in the absence of portal hypertension. Moreover, our case also suggests that it might be possible to decide PVA treatment based on etiology.

REFERENCES

- 1 **Barzilai R**, Kleckner MS Jr. Hemocholecyst following ruptured aneurysm of portal vein; report of a case. *AMA Arch Surg* 1956; **72**: 725-727
- 2 **Leonsins AJ**, Siew S. Fusiform aneurysmal dilatation of the portal vein. *Postgrad Med J* 1960; **36**: 570-574
- 3 **Sedgwick CE**. Cisternal dilatation of portal vein associated with portal hypertension and partial biliary obstruction. *Lancet Clin Bull* 1960; **11**: 234-237
- 4 **Hermann RE**, Shafer WH. Aneurysm of the portal vein and portal hypertension: first reported case. *Ann Surg* 1965; **162**: 1101-1104
- 5 **Liebowitz HR**, Rousselot LM. Saccular aneurysm of portal vein with agnogenic myeloid metaplasia. *N Y State J Med* 1967; **67**: 1443-1447
- 6 **Thomas TV**. Aneurysm of the portal vein: report of two cases, one resulting in thrombosis and spontaneous rupture. *Surgery* 1967; **61**: 550-555
- 7 **Vine HS**, Sequeira JC, Widrich WC, Sacks BA. Portal vein aneurysm. *AJR Am J Roentgenol* 1979; **132**: 557-560
- 8 **Boyez M**, Fourcade Y, Sebag A, Valette M. Aneurysmal dilatation of the portal vein: a case diagnosed by real-time ultrasonography. *Gastrointest Radiol* 1986; **11**: 319-321
- 9 **Thompson PB**, Oldham KT, Bedi DG, Guice KS, Davis M. Aneurysmal malformation of the extrahepatic portal vein. *Am J Gastroenterol* 1986; **81**: 695-697
- 10 **Andoh K**, Tanohata K, Asakura K, Katsumata Y, Nagashima

- T, Kitoh F. CT demonstration of portal vein aneurysm. *J Comput Assist Tomogr* 1988; **12**: 325-327
- 11 **Lee HC**, Yang YC, Shih SL, Chiang HJ. Aneurysmal dilatation of the portal vein. *J Pediatr Gastroenterol Nutr* 1989; **8**: 387-389
- 12 **Baker BK**, Nepute JA. Computed tomography demonstration of acute thrombosis of a portal vein aneurysm. *Mo Med* 1990; **87**: 228-230
- 13 **Hagiwara H**, Kasahara A, Kono M, Kashio S, Kaneko A, Okuno A, Hayashi N, Fusamoto H, Kamada T. Extrahepatic portal vein aneurysm associated with a tortuous portal vein. *Gastroenterology* 1991; **100**: 818-821
- 14 **Dognini L**, Carreri AL, Moscatelli G. Aneurysm of the portal vein: ultrasound and computed tomography identification. *J Clin Ultrasound* 1991; **19**: 178-182
- 15 **Glazer S**, Gaspar MR, Esposito V, Harrison L. Extrahepatic portal vein aneurysm: report of a case treated by thrombectomy and aneurysmorrhaphy. *Ann Vasc Surg* 1992; **6**: 338-343
- 16 **Brock PA**, Jordan PH Jr, Barth MH, Rose AG. Portal vein aneurysm: a rare but important vascular condition. *Surgery* 1997; **121**: 105-108
- 17 **Miyauchi A**, Okada S, Hashimoto T, Wakabayashi H, Maeba T, Tanaka S, Hayashi H. Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. *Surg Today* 1995; **25**: 855-858

S- Editor Wang JL **L- Editor** Hughes D **E- Editor** Zheng XM



ACKNOWLEDGMENTS

Acknowledgments to reviewers of *World Journal of Gastrointestinal Surgery*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Gastrointestinal Surgery*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Ned Abraham, MBBS, FRACS, FRCS, PhD, Coffs Colorectal and Capsule Endoscopy Centre, University of New South Wales, 187 Rose Avenue, PO Box 2244, Coffs Harbour, NSW 2450, Australia

Chapel Alain, PhD, Department of Men Radioprotection, Laboratory of Radio Pathology and Innovative Therapy, Institute of nuclear Safety and radioprotection, PO Box 17, Far 92262, France

Vollmar Brigitte, MD, Professor, Institute of Experimental Surgery, University of Rostock, Schillingallee 69a, Rostock 18057, Germany

Chien-Hung Chen, MD, PhD, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei 100, Taiwan, China

Stavros J Gourgiotis, MD, PhD, Department of Second Surgical, 401 General Army Hospital of Athens, 41 Zakinthinou Street, Papagou, Athens 15669, Greece

Helena M Isoniemi, MD, PhD, Professor, Transplantation and Liver Surgery Clinic, Helsinki University Hospital, box 263, Helsinki 00029-HUCH, Finland

Chen-Guo Ker, MD, PhD, Professor, Department of Surgery, Kaohsiung Medical University, No. 100, Tz-You 1st Rd, Kaohsiung, Taiwan, China

Adnan Narci, Professor, Department of Pediatric Surgery, Afyon Kocatepe University School of Medicine, Izmir Street, 7km, Afyonkarahisar 03200, Turkey

Marcelo AF Ribeiro, MD, PhD, TCBC, TCBCD, FACS, Department of Surgery, Santo Amaro University, Alameda Gregorio Bogossian Sobrinho, 80/155, Santana de Parnaiba, SP 06543-385, Brazil

Sukamal Saha, MD, FACS, FRCS, FICS, Department of Orthopedics, 3500 Calkins Rd, Suite A, Flint, MI 48532, United States

Manuela Santos, PhD, Associate Professor, Department of Medicine, University of Montreal, Montreal Cancer Institute, CRCHUM/Notre-Dame Hospital, Pavillon De Seve Y5625, 1560 Sherbrooke Est, Montreal, QC, H2L 4M1, Canada

Christian Max Schmidt, MD, PhD, MBA, FACS, Departments of Surgery and Biochemistry/Molecular Biology, Indiana University School of Medicine, 980 W Walnut St C522, Indianapolis, IN 46202, United States

Gregory Peter Sergeant, MD, Department of General Surgery, University Hospital Leuven, Herestraat 49, Leuven B-3000, Belgium

Douglas S Tyler, MD, Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, United States

Marcus VM Valadao, MD, Instituto Nacional de Cancer, Hospital do Cancer Unidade I, Hc2., Rua do Equador 831, Santo Cristo, Rio de Janeiro 20220-410, RJ, Brazil

Caroline S Verbeke, MD, PhD, Department of Histopathology, Bexley Wing Level 5 St James's University, Hospital Beckett Street, Leeds LS9 7TF, United Kingdom



Meetings

Events Calendar 2011

January 15-19, 2011
EAES Advanced Laparoscopic GI
Surgery Course, Cairo, Egypt

January 20-22, 2011
Gastrointestinal Cancers Symposium
(ASCO GI), San Francisco, CA,
United States

January 26-30, 2011
5th UK Alpine Liver and Pancreatic
Surgery Meeting, Carlo Magno
Zeledria Hotel, Madonna di
Campiglio, Italy

February 01-03, 2011
6th Annual Academic Surgical
Congress, Huntington Beach, CA,
United States

February 21-26, 2011
Minimally Invasive Surgery
Symposium 2011, The Grand

America Hotel, Salt Lake City, Utah,
United States

March 03-06, 2011
The Society of Surgical Oncology
63rd Annual Meeting, San Antonio,
TX, United States

March 10-13, 2011
The American Hepato-Pancreato-
Biliary Association Annual Meeting,
Miami Beach, FL, United States

March 14-17, 2011
British Society for Gastroenterology
Annual Meeting, International
Convention Centre, Birmingham,
United Kingdom

March 25-27, 2011
NZAGS Conference 2011 GI Surgery,
New Plymouth, New Zealand

March 30-April 02, 2011
The Society of American
Gastrointestinal and Endoscopic
Surgeons 2011 Annual Meeting, San
Antonio Convention Center, San
Antonio, TX, United States

April 02-06, 2011
The American Association for

Cancer Research 102nd Annual
Meeting, Orlando, FL, United States

April 10-12, 2011
The American Association of
Endocrine Surgeons 32nd Annual
Meeting, Houston, TX, United States

April 14-16, 2011
The American Surgical Association
131st Annual Meeting, Boca Raton,
FL, United States

May 07-10, 2011
Digestive Disease Week, Chicago,
IL, United States

May 07-10, 2011
45th Annual Meeting of the Pancreas
Club, Chicago, IL, United States

June 15-18, 2011
19th International Congress of
the European Association for
Endoscopic Surgery, in collaboration
with and incorporating the 15th
National Congress of the Italian
Society of Endoscopic Surgery,
Torino, Italy

September 10-14, 2011
International Congress of

Endoscopy, Los Angeles, CA,
United States

September 22-24, 2011
5th joint EAES and ESGE, European
Workshop on NOTES, Frankfurt,
Germany

September 23-25, 2011
The New England Surgical Society
92nd Annual Meeting, Breton
Woods, NH, United States

September 23-27, 2011
ECCO-European Society for Medical
Oncology Congress, Stockholm,
Sweden

October 23-27, 2011
The American College of Surgeons
97th Annual Clinical Congress, San
Francisco, CA, United States

November 02-05, 2011
American Pancreatic Association
42nd Annual Meeting, Chicago, IL,
United States

November 13-16, 2011
The Western Surgical Association
119th Scientific Session, Tucson, AZ,
United States



Instructions to authors

GENERAL INFORMATION

World Journal of Gastrointestinal Surgery (*World J Gastrointest Surg*, *WJGS*, online ISSN 1948-9366, DOI: 10.4240), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 336 experts in gastrointestinal surgery from 35 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJGS* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJGS* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJGS* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of edi-

torial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of *WJGS* is to rapidly report the most recent results in basic and clinical research on gastrointestinal surgery, specifically including micro-invasive surgery, laparoscopy, hepatic surgery, biliary surgery, pancreatic surgery, splenic surgery, surgical nutrition, portal hypertension, as well as the associated subjects such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, genetics, genomics, proteomics, pharmacology, pharmacokinetics, pharmacogenetics, molecular biology, clinical trials, diagnosis and therapeutics and multimodality treatment. Emphasis is placed on original research articles and clinical case reports. This journal will also provide balanced, extensive and timely review articles on selected topics.

Columns

The columns in the issues of *WJGS* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Article: To report innovative and original findings in gastrointestinal surgery; (9) Brief Article: To briefly report the novel and innovative findings in gastrointestinal surgery; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJGS*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of gastrointestinal surgery; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on basic research and clinical practice in gastrointestinal surgery.

Name of journal

World Journal of Gastrointestinal Surgery

Serial publication number

ISSN 1948-9366 (online)

Indexing/abstracting

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the

Instructions to authors

authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGS* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must

clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1948-9366/office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/1948-9366/g_info_20100305152206.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjgs@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-

Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJGS*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/1948-9366/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ... *etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. $^aP < 0.05$, $^bP < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of *P* values, $^cP < 0.05$ and $^dP < 0.01$ are used. A third series of *P* values can be expressed as $^eP < 0.05$ and $^fP < 0.01$. Other notes in tables or under illustrations should be expressed as 1F , 2F , 3F ; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

Instructions to authors

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 ± 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: http://www.wjgnet.com/1948-9366/g_info_20100312191949.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and

Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindII*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

Editorial: http://www.wjgnet.com/1948-9366/g_info_20100312190249.htm

Frontier: http://www.wjgnet.com/1948-9366/g_info_20100312190321.htm

Topic highlight: http://www.wjgnet.com/1948-9366/g_info_20100312190447.htm

Observation: http://www.wjgnet.com/1948-9366/g_info_20100312190550.htm

Guidelines for basic research: http://www.wjgnet.com/1948-9366/g_info_20100312190653.htm

Guidelines for clinical practice: http://www.wjgnet.com/1948-9366/g_info_20100312190758.htm

Review: http://www.wjgnet.com/1948-9366/g_info_20100312190907.htm

Original articles: http://www.wjgnet.com/1948-9366/g_info_20100312191047.htm

Brief articles: http://www.wjgnet.com/1948-9366/g_info_20100312191203.htm

Case report: http://www.wjgnet.com/1948-9366/g_info_20100312191328.htm

Letters to the editor: http://www.wjgnet.com/1948-9366/g_info_20100312191431.htm

Book reviews: http://www.wjgnet.com/1948-9366/g_info_20100312191548.htm

Guidelines: http://www.wjgnet.com/1948-9366/g_info_20100312191635.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJGS*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office

World Journal of Gastrointestinal Surgery

Editorial Department: Room 903, Building D,
Ocean International Center,
No. 62 Dongsihuan Zhonglu,
Chaoyang District, Beijing 100025, China
E-mail: wjgs@wjgnet.com
<http://www.wjgnet.com>
Telephone: +86-10-85381891
Fax: +86-10-85381893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/1948-9366/g_info_20100312191901.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/1948-9366/g_info_20100312191818.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJGS will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJGS is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.